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Aims: To examine the cost-effectiveness of hepatitis C (HCV) treatment of people who inject 
drugs (PWID), combined with medication-assisted treatment (MAT) and syringe-service 
programs (SSP), to tackle the increasing HCV epidemic in the United States.  
Design: HCV-transmission and disease progression models with cost-effectiveness analysis 
using a health care perspective and measuring benefits in quality-adjusted life-years (QALYs). 
Setting: Rural Perry County, Kentucky (PC), and urban San Francisco, California (SF),USA. 
Compared with PC, SF has a greater proportion of PWID with access to MAT or SSP. HCV 
treatment of PWID is negligible in both settings. 
Participants: PWID, data collected between 1998 and 2015 from Social Networks Among 
Appalachian People, U Find Out, Urban Health Study, and National HIV Behavioral 
Surveillance System studies. 
Measurements: Three intervention scenarios modeled: baseline—existing SSP and MAT 
coverage with HCV screening and treatment with direct-acting antiviral for ex-injectors only as 
per standard of care; Intervention 1—scale-up of SSP and MAT without changes to treatment; 
and Intervention 2—scale-up as Intervention 1 combined with HCV screening and treatment for 
current PWID. Incremental cost-effectiveness ratios (ICERs) and uncertainty using cost-
effectiveness acceptability curves. 
Findings: For both settings, Intervention 2 is preferred to Intervention 1 and the appropriate 
comparator for Intervention 2 is the baseline scenario. Relative to baseline, for PC Intervention 2 
averts 1,852 more HCV infections, increases QALYS by 3,095, costs $21.6 million more, and 
has an ICER of $6,975/QALY. For SF, Intervention 2 averts 36,473 more HCV infections, 
increases QALYs by 78,93, costs $ 872 million more, and has an ICER of $11,044/QALY. The 




Conclusions: Hepatitis C screening and treatment for people who inject drugs, combined with 
medication-assisted treatment and syringe-service programs, is a cost-effective strategy for 




Hepatitis C virus (HCV) is a blood-borne virus that usually results in life-long chronic 
infection that can lead to liver disease and death. In 2010, an estimated 3.5 million Americans 
had chronic HCV infection [1], and in 2015 there were 19,629 deaths reported to CDC with HCV 
listed on the death certificate [2]. If not addressed, the HCV-associated cost burden will remain 
substantial. Total healthcare cost associated with HCV infection was $6.5 billion in 2011, with 
an expected peak in 2024 at $9.1 billion [3]. 
HCV is primarily transmitted through injection drug use in the United States [4], with a 
seroprevalence above 50% among people who inject drugs (PWID) [5-8]. Many parts of the 
United States, particularly rural areas, are experiencing an epidemic of prescription and illicit 
opioid use, including heroin and fentanyl, with corresponding large increases in HCV infection 
[9, 10]. 
A recent treatment revolution brought new direct-acting antiviral treatments (DAAs) for 
HCV infection, with high efficacy (sustained viral response [SVR] or cure rate > 90%), short 
duration (8-12 weeks) and few side-effects [11]. Although prices have dramatically declined, the 
high treatment cost ($26,400 for the cheapest pan-genotype drug approved so far [12]) and the 
large number needing treatment raise questions of affordability for scaling up treatment rates. 
Guidelines recommend infected individuals to be treated [11]. However, payer policies 
deter HCV treatment for PWID [13]. Medication-assisted treatment (MAT, principally methadone 
or buprenorphine) and syringe-service programs (SSPs) can reduce the risk of HCV acquisition 
among PWID. Combining MAT and SSP with HCV treatment can impact both incidence and 
prevalence of HCV infection, and may be more effective in reducing the transmission of HCV 
among PWID than any one of those strategies alone [14]. Therefore, a comprehensive approach to 
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cost-effectiveness assessment necessitates inclusion of comprehensive programs comprised of 
MAT, SSP and HCV screening and treatment. 
The objective of this analysis is to evaluate the cost-effectiveness of scaling up MAT and 
SSP paired with or without HCV screening and DAA treatment for PWID. We evaluated these 
interventions in one rural and one urban U.S. setting. 
METHODS 
Model Description 
Our analysis uses two validated dynamic, deterministic, compartmental models of HCV-
transmission and disease progression among current and ex-PWID [15]. One model is used for 
Perry County, Kentucky (PC), and the other is used for San Francisco (SF). The models used for 
the two locations vary slightly, reflecting different demographics and injecting drug use 
dynamics. Models were stratified by age (SF) or injection duration (PC); intervention status 
(MAT, SSP, or no intervention); and low- or high-risk behavior (defined as sharing injection 
equipment in the past 6 months). The rate of HCV transmission depends on the prevalence of 
HCV among the PWID population, MAT/SSP status, HCV treatment status, low- or high-risk 
status, and age or injection duration. Once infected, individuals either spontaneously clear 
infection or develop life-long chronic infection. However, if diagnosed, most people who are 
HCV-infected, including PWID, may receive antiviral treatment. People who achieve SVR are 
no longer infectious but may become re-infected at the same rate as susceptible PWID and can 
then be re-treated. 
Population 
We separately modeled the PWID population in urban SF and rural PC. These locations 
characterize two types of U.S. PWID populations; SF has an older stable population of PWID 
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who primarily inject heroin with relatively high coverage of SSP and moderate coverage of MAT 
[16, 17]; whereas PC’s PWID population is young and increasing, primarily injects prescription 
opioids, and has no SSP (after model building an SSP has been in place since April 2, 2018) and 
limited MAT [5, 18]. 
Model Parameterization 
The PC model used data from the Social Networks Among Appalachian People (SNAP) 
cohort study [5], which recruited PWID in PC. The model assumed an increasing PWID 
population size between 1990 and 2000 with an estimated 700 PWID in 2009. At baseline, MAT 
coverage was assumed to be low (4.7%) with no SSP or HCV treatment for current PWID. In 
2009, the HCV seroprevalence among PWID was 53.3% and HCV incidence during follow-up 
(2008–2015) was 18.3 per 100 person-years (pyrs). 
The SF model was parameterized to data from the UFO study [19, 20], the National HIV 
Behavioral Surveillance System (NHBS) [21], and the Urban Health Study (UHS) [22]. The model 
assumed an aging (20% of PWID < 30 years old) and slowly decreasing PWID population, with 
an estimated 30,000 PWID in 2007 [18]. At baseline, MAT coverage was assumed to be low-
moderate (12%), with high SSP coverage since the late 90s (84%), but no HCV treatment for 
current PWID. In the absence of recent data, UHS data from 1998–2000 estimated the HCV 
seroprevalence among PWID younger than 30 as 60.8%, those 30 to 49 as 93.5%, and those 
older than 50 as 96.3% [22]. The HCV incidence among PWID younger than 30 years was 25.1 
per 100pyrs in 2001, remaining stable since then [23, 24]. 
For both models, we assume MAT and SSP reduce HCV transmission risk based on a 
recent Cochrane review [25], by 50% and 56% for MAT and SSP on their own, respectively, and 
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by 72% if on both (product of the risk ratios). The SVR rate of DAAs was varied between 85-
95% (Table 1). 
Model Calibration 
Five thousand parameter sets were sampled from the parameter uncertainty ranges for 
each setting. First, each model was initially calibrated to population demographics in each 
setting, which allowed for injecting increases in the 1990s in PC but decreases in SF. Second 
both models were fit to the coverage of MAT and SSP in each setting and the proportion of 
PWID at high risk. Lastly, the PC model was fitted to the HCV seroprevalence among PWID 
injecting for less than 3 years, and the SF model to the HCV incidence in PWID younger than 30 
and seroprevalence in PWID older than 50. Model projections were validated with prevalence in 
those injecting over three years and HCV incidence in PC, and prevalence in those aged under 30 
in SF. More details on model structure, parameterization and calibration are in the accompanying 
paper  and summarized in Appendix 1. 
Intervention Scenarios 
The time horizon for our analyses was 10 years of intervention (2017–2026) followed by 
50-year follow-up (2027–2076) at baseline levels of intervention coverage to capture long-term 
prevention and morbidity benefits. For our main analysis, we considered three intervention 
scenarios: 
• Baseline: Maintain current levels of SSP (0% in PC and 84% in SF) and MAT (4.7% 
in PC and 12% in SF) with existing HCV care and treatment. This includes usual 
HCV screening and treatment with DAAs for persons who formerly injected drugs 
but not for those currently injecting. For persons who formerly injected drugs, this 
includes annual screening of 2%–10% for persons with asymptomatic disease 
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(fibrosis stages F0–F3) and 25%–50% for persons with more progressed disease [26-
28], followed by treatment of 10%–20% for any diagnosed individual [29-31]. 
• Intervention 1 (Scale-up MAT and SSP): Scale-up of SSP (only applicable for PC) 
and MAT to 50% coverage with no change in screening and treatment rates. 
• Intervention 2 (Scale-up MAT and SSP plus HCV treatment for PWID): Scale-up of 
SSP and MAT as for Intervention 1, plus annual screening of 90% of PWID for HCV, 
followed by treatment with DAAs for 90% of diagnosed PWID. 
Costs and Health Outcomes 
The perspective on costs was that of the third-party payer (2016 prices). The model 
included costs for HCV screening with a rapid test, laboratory-confirmatory testing (RNA test) 
for all positives, and other laboratory tests (markers of liver disease) for all diagnosed individuals 
[32-35]. Existing studies were used to get the costs of MAT with methadone [36] and the costs of 
SSP [37]. HCV treatment costs included the current average cost of DAAs and costs for treatment 
monitoring [11, 33]. The model also included the estimated health care costs associated with 
different HCV-related disease stages [38], and annual monitoring costs after achieving SVR [38]. 
Input costs and sources are in Table 1 with more details in Appendix 2. 
Main model health outcomes were the number of new HCV infections and quality-
adjusted life-years (QALYs). QALYs were estimated using existing Canadian utility weights 
unadjusted by the Canadian population norm [39, 40], adjusted both to the U.S. population [41], and 
to account for lower utilities among PWID (than general population) which are heightened 
among PWID on MAT [42] (see Table 1). All costs and QALYs were discounted at 3% annually. 




Incremental cost-effectiveness ratios (ICERs; additional cost to gain one QALY) 
comparing non-dominated scenarios were estimated [43]. A scenario is dominated (i.e. not cost-
effective) if it is more expensive and less effective (strict dominance) than another, or if it has a 
higher ICER than a more costly intervention (extended dominance)[44]. The preferred scenario is 
determined by comparing the ICER with what decision makers are willing to pay for an 
additional QALY. There is no consensus on decision makers’ willingness-to-pay (WTP) in the 
United States, although a threshold of $50,000 to $100,000 per QALY saved has been used 
elsewhere [45, 46].  
Uncertainty in the model projections was assessed using cost-effectiveness acceptability 
curves (CEACs) to graphically show the probability that each strategy is the most cost-effective 
based on different WTP thresholds [43, 44]. Uncertainty distributions for each parameter are given 
in Table 1 (costs and utilities) and Appendix 2 (other parameters). Five thousand parameter 
draws were randomly sampled from these distributions, and the model was run for each scenario 
to give a distribution of model outcomes. The analysis conformed to good practice guidelines on 
cost-effectiveness analyses [47]. 
Sensitivity Analyses 
We conducted 9 one-way sensitivity analyses to test the robustness of our results to 
variations in key parameters. 1. To account for further reductions in the cost of DAAs due to the 
recent announcement of generic DAAs [48], we reduced the cost of DAAs by 25%, 50%, and 
75%. 2. To analyze the impact of lower DAA effectiveness, the SVR rate was reduced from 
between 85-95% to between 70% and 80%. 3. The impact of the time horizon of the analysis was 
assessed by changing it from 60 years to 35 and 110 years (maintaining 10 years of intervention). 
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4. Intervention 2 includes nearly universal screening (90%) and HCV treatment uptake (90%), 
based on current guidelines. We considered less favorable assumption for screening (45%) and 
treatment uptake (45%). 5. We conducted 3 separate sensitivity analysis on our utility values. 5.1 
We assessed the impact of using lower utility values, as reported in Wittenberg et al. (2016), for 
PWID not in MAT (0.574 instead of base-case 0.8), and PWID in MAT (0.722 instead of base-
case 0.9). 5.2 We also assessed the impact of using the minimum quality of life estimator with 
our baseline utility values, which assigns the lower individual value of multiple co-morbid 
conditions in this population (Wittenberg et al., 2017). 5.3 Finally, we assessed the impact of 
using both lower utility values and the minimum quality of life estimator. 6. Because the time 
constraints of pretest counseling make its widespread adoption unlikely, we conducted a 
sensitivity analysis that excluded the cost of pre-test counseling ($16) from screening costs. 7. To 
account for the possibility of higher treatment rates for diagnosed persons who formerly injected 
drugs, we assumed 53.8% of diagnosed persons who formerly injected drugs would be treated 
[49], instead of the base-case assumptions of only 10-20% [29-31]. 8. To account for a possible 
lower HCV prevalence in San Francisco, for those older than 50 we changed the base-case value 
of 96% to 75.6% (64.6% – 86.6%), based on the results of rapid testing from the latest 2018 
NHBS round [50, 51] which reported prevalence using voluntary testing. 9. Finally, we assessed the 
impact of accounting for an increased risk of death in the four weeks before and after starting 
MAT [52]. 
To ascertain which parameters were most important in contributing to the uncertainty in 
the incremental cost and QALYs gained, we performed analyses of covariance (ANCOVA) [53-
55]. The proportion of the sum of squares contributed by each parameter was calculated to 





Table 2 presents the number of infections, QALYs, costs and ICER for each setting. 
Other base-case outcomes associated with each strategy, including life-years, numbers reached, 
cumulative number of complications, and disaggregated costs, are in Appendix 3. 
In both PC and SF, Intervention 1 is not cost-effective (Intervention 2 is preferred 
through extended dominance) and the appropriate comparator for Intervention 2 is the baseline 
scenario. For PC, relative to baseline, Intervention 2 averted 1,852 more HCV infections and 
gained 3,095 QALYS, for an additional cost of $21.6 million, and an ICER of $6,975 per QALY 
gained. For SF, relative to baseline, Intervention 2 averted 36,473 more HCV infections and 
gained 78,939 QALYs, for an additional costs of $ 872 million, and an ICER of $11,044 per 
QALY gained. 
(Insert Table 2) 
Figure 1a shows that in PC the baseline scenario is the most cost-effective intervention 
for WTP values below $6,000 per QALY. For WTP values above $6,000, scale-up of MAT and 
SSP and HCV screening and treatment for PWID (Intervention 2) becomes most cost-effective 
and achieves a higher than 95% probability of being cost-effective for WTP values above 
$19,000 per QALY gained. Figure 1b shows that in SF, the baseline scenario is the most cost-
effective intervention for WTP values below $10,000 per QALY, after which Intervention 2 is 
more cost-effective, achieving a higher than 95% probability of being cost-effective for WTP 
values above $28,000 per QALY. 




For both settings, the ICER for Intervention 2 compared with the baseline scenario was 
most sensitive to reductions in the cost of DAAs, changes in the time horizon of the analysis, and 
reductions in screening and HCV treatment uptake (see Figure 2). 1. In both settings, 
Intervention 2 became even more cost-effective, with ICERs below $5,000/QALY, when using a 
cost of DAAs similar to the cost of the less expensive DAAs currently in the market (50% below 
baseline value). 2. Decreasing the SVR rate of DAAs slightly increased the ICER (less cost-
effective) in both settings. 3. Increasing the time horizon improved the ICER in SF and PC. 
Conversely, shortening the time horizon made the intervention less cost-effective. 4. Reducing 
screening and HCV treatment uptake rates to 45% each, increased the ICER from 6,975/ QALY 
to $12,240 per QALY in PC, and from $11,044/ QALY to $14,606 per QALY in SF. 5. Using 
the minimum utility estimator resulted in slightly lower quality of life gains with Intervention 2 
because the utility values for those not in MAT are always lower than HCV states, making the 
quality-of-life benefit from HCV treatment only observable if the individual is on MAT and for 
the cirrhosis health state and subsequent stages of chronic HCV disease. Nevertheless, for all 
sensitivity analysis on the QoL estimates, the ICERs were very close to the baseline values. 6. 
Excluding the cost of pre-test counseling had a minimal impact on the ICERs for both sites. 7. 
Assuming a higher treatment rate of diagnosed persons who formerly injected drugs, 
considerably improved the ICER for Kentucky ($4,516/ QALY), and slightly improved the ICER 
for San Francisco ($10,676/ QALY). 8. Using a lower prevalence of HCV among those older 
than 50 in SF resulted in a slightly increased ICER of 13,537/ QALY. 9. Accounting for the 
increased risk of death before and after MAT led to a modest increase in the ICER in both 
Kentucky ($7,581/ QALY) and San Francisco ($11,338/ QALY). 




In the ANCOVA of costs, uncertainty in the cost of HCV treatment accounted for most 
(55% in PC and 84% in SF) of the variation in incremental costs in both settings. Uncertainty in 
the duration of injection (22%) and the HCV seroprevalence among those injecting <3 years 
(5%) also played an important role in PC. In the ANCOVA of QALYs, uncertainty in the PWID 
population sizes (26% in PC and 60% in SF), and utility weights associated with being in health 
states F0 or F1 (41% in PC and 11% in SF in total) were the main factors accounting for the 
variation in the incremental QALYs in both settings. 
DISCUSSION 
The current epidemic of opioid abuse in the United States has led to striking increases in 
HCV infection, particularly due to increasing injection drug use in rural settings [9, 56]. Therefore, 
targeting PWID for HCV prevention and treatment is critically important for controlling HCV in 
the United States [57]. Considering an integrated health care strategy in two settings, our results 
show that scaling up MAT and SSP, combined with HCV screening and treatment for PWID can 
be a highly cost-effective approach to reversing the increasing HCV incidence in the United 
States. This applies both in an urban setting with long-standing injection drug use and moderate 
to high coverage of MAT and SSP interventions, and in a rural setting with recent increases in 
injection drug use with negligible coverage of harm-reduction interventions. We show that a 
combined prevention and treatment approach optimizes the HCV prevention benefits achieved, 
with the expansion of MAT and SSP directly reducing the risk of new infections, while DAA 




The ICER for the combined intervention was $6,975 per QALY for PC and $11,044 per 
QALY for SF, which by most standards suggests that HCV screening and treatment of current 
PWID combined with SSP and MAT scale-up is highly cost-effective in reducing current HCV 
infections and preventing new ones. However, although cost-effective, it is important to note that 
most intervention costs (HCV screening and treatment among PWID and MAT and SSP scale-
up) are upfront while the health care benefits and costs averted occur many years down the line, 
so the intervention is less cost-effective when viewed over shorter time frames. 
Our results are based on model projections and need to be interpreted with the 
recognition of several simplifying assumptions. First, we restricted our analysis to direct medical 
costs. We did not consider the effect of HCV treatment on increasing productivity or any extra-
hepatic benefits of treatment [58, 59]. We also did not incorporate the beneficial effects of MAT on 
HIV-transmission or HIV-treatment outcomes [60-62], on decreasing overdose risk,the number of 
PWID [63], and criminal activity [64], and improving employment status [65]. Including these 
effects would improve the cost-effectiveness of scaling up HCV treatment and MAT. We also 
did not account for patient out-of-pocket costs or costs accrued from prolonged life expectancy 
[66], which would have reduced the cost-effectiveness of our intervention. Impacts of MAT 
beyond reduction in HCV transmission can be addressed in a model that explicitly incorporates 
the natural history of opioid use disorder; the current model focuses on the dynamics of HCV 
infection amongst PWID. 
Second, we assumed that the risk of reinfection was equal to that of initial infection. It is 
possible that PWID may reduce their risk behavior after HCV treatment [67] and also have a 




Third, we did not account for heterogeneity in treatment compliance (e.g., high-risk 
individuals may be less likely to enter or comply with treatment). These limitations can be 
addressed in future modeling that uses empirical research on the effect of patient characteristics 
on HCV treatment access and compliance. 
Fourth, our results were subject to limitations in data availability, particularly 
surrounding SSP costs and parameterizing and calibrating the model. Most importantly, these 
included limited data on the evolving injecting and HCV epidemic in both PC and SF. Our 
model projections included uncertainty in these factors, and although they were robust despite 
this, they could be improved with better data on these factors. Additionally, our baseline scenario 
for SF assumes no HCV treatment for active PWID. In 2016, SF initiated an aggressive 
campaign to eliminate HCV that promotes HCV treatment for at-risk groups, including PWID. 
Treatment rates are increasing, but specific rates for PWID are not available [70]. 
Recent health economic models for several settings (United Kingdom, Australia, 
Netherlands) suggest that early HCV treatment for PWID is likely to be cost-effective [71-74]. 
However, these previous cost-effectiveness analyses were not conducted in a U.S. setting and did 
not consider the joint impact of scaling up HCV treatment together with MAT and SSP. Other 
cost-effectiveness analyses of DAA treatment have been conducted in the United States [40, 75]; 
but none of those analyses focused on treatment of PWID in a community setting. Our study is 
the first cost-effectiveness analysis of U.S. HCV treatment combined with MAT and SSP for 
PWID. 
Despite the high incidence of HCV in PWID and professional society guidelines and 
recommendations advocating HCV treatment for PWID [76, 77], few active PWID have received 
treatment for HCV [77, 78]. Reaching and engaging PWID has challenges associated with the illicit 
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nature of injecting drug use and stigma, discrimination, and mistrust of health services [78]. 
However, successful treatment outcomes have been achieved in numerous settings, with 
integration of HCV care in substance use treatment settings or co-locating primary health care 
services and behavioral health services, including MAT and SSP, likely enhancing medication 
adherence [79]. Unfortunately, the cost of new DAA treatments and the high number needing 
treatment, Medicaid requirements for drug and alcohol abstinence, and restricting treatment to 
those with late-stage liver disease have curbed the use of HCV treatment as a prevention strategy 
in the United States. [80, 81]. Recently, competition between different DAA drug manufacturers 
has resulted in substantial decreases in the costs of HCV medications [11], while Medicaid’s 
ability to negotiate prices and easing of restrictions on treatment [82, 83] bring hope for the 
feasibility of HCV treatment as prevention in PWID. Also encouraging is the recent declaration 
by the President’s Commission on Combating Drug Addiction and the Opioid Crisis which led 
the president to declare the country’s opioid crisis a national emergency [84]. One of the 
commission’s recommendations is enhancing access to MAT, with such scale-up being an 
important avenue for a concomitant scale-up in HCV treatment among PWID. 
Conclusions 
Our study is the first to examine the cost-effectiveness of HCV treatment as prevention in 
U.S. rural and urban settings. Despite differences in the injecting epidemics, availability of MAT 
and SSP, and HCV epidemiology in the two settings, scaling up HCV treatment combined with 
MAT and SSP is a cost-effective approach for reducing HCV transmission in both settings. This 
finding may support policy change to reduce disparities in the management of HCV infection 
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Table 1. Model Parameters: Treatment Effects, Costs and Utilities 
 Perry County San Francisco  
Input Parameter Value Distribution (a,b) Value Distribution (a,b) Reference 
Effect of MAT, SSP and DAAs 
Relative risk of acquiring HCV 
while on MAT 
0.5 
Log-normal 
(-0.69, 0.013) 0.5 
Log-normal  
(-0.69, 0.013) Platt et al., 2017 [25] 
Relative risk of acquiring HCV 
while on SSP 
0.44 
Log-normal 
(-0.82, 0.094) 0.44 
Log-normal 
(-0.82, 0.094) Platt et al., 2017 [25] 
Relative risk of acquiring HCV 
while on MAT+SSP Product of relative risk for MAT and SSP  
DAA SVR rate 85-95% Uniform 85-95% Uniform AASL 2017 [11] 
Screening and diagnosis costs, 2016 USD 
Screening with rapid test 
(negative result) 
35 Gamma (15, 2) 28 Gamma (15, 2) Cipriano et al., 2012 [32]; 
Medicaid, 2016 [33]; SAMHSA 
2016 [35] 
Screening with rapid test 
(positive result) and diagnosis 
(negative RNA) 
105 Gamma (15, 7) 79 Gamma (15, 5) 
Screening with rapid test 
(positive result) and diagnosis 
(positive RNA) and labs 
569 Gamma (15, 37) 375 Gamma (15, 24) 
MAT and SSP per person costs, 2016 USD 
Methadone treatment, per day 14 Gamma (198, 0) 14 Gamma (198, 0) Jackson et al., 2015 [36] 
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SSP, per year 127 Gamma (15, 8) 127 Gamma (15, 8) Nguyen et al., 2014 [37]; 
Bluthenthal et al., 2015 [85]; 
personal communication with 
Michael Discepola (2016) and 
Henry Fisher Raymond (2015)  
HCV treatment per person costs, 2016 USD 
Antiviral therapy 58,906 Gamma (3, 
17381) 
59,466 Gamma (3, 17371) AASL 2017 [11], Medicaid, 2016 
[33] 
HCV treatment monitoring 
(12 weeks) 
443 Gamma (15, 29) 274 Gamma (15, 18) 
Complications costs 
F0-F4 (without antiviral 
treatment) 
793 Gamma (2, 330) 793 Gamma (2, 330) Rein et al., 2015 [38] 
CC (without antiviral 
treatment) 
1,509 Gamma (9, 161) 1,509 Gamma (9, 161) 
DC (without antiviral 
treatment) 
20,348 Gamma (39, 517) 20,348 Gamma (39, 517) 
HCC 42,833 Gamma (73, 588) 42,833 Gamma (73, 588) 
1 year after liver transplant 200,458 Gamma (80, 
2,512) 
200,458 Gamma (80, 2,512) 
>1 year after liver transplant 36,203 Gamma (148, 
245) 
36,203 Gamma (148, 245) 
Annual monitoring cost after 
SVR 




Quality-of-life multipliers for each health state 
IFN-free therapy-related 
multiplier 
0.95 Beta (108, 6) 0.95 Beta (108, 6) Chong et al. [39]; Chhatwal et al. 
[40] 
F0, F1 0.93 Beta (47, 4) 0.93 Beta (47, 4) 
F2, F3 0.93 Beta (47, 4) 0.93 Beta (47, 4) 
Compensated Cirrhosis 0.9 Beta (31,3) 0.9 Beta (31,3) 
DC 0.8 Beta (12, 3) 0.8 Beta (12, 3) 
HCC 0.79 Beta (11, 3) 0.79 Beta (11, 3) 
First year, post-liver 
transplant 
0.84 Beta (54, 10) 0.84 Beta (54, 10) 
Post SVR 1 Beta (3,834, 4) 1 Beta (3834, 4) 
Quality-of-life multipliers for PWID 
PWID not on MAT 0.8 — 0.8 — Zaric et al., 2000 [42] 
PWID on MAT 0.9 — 0.9 — 
PWID on SSP 0.8 — 0.8 — Assumed 
CC = compensated cirrhosis; DAA= direct-acting antiviral treatments; DC = decompensated cirrhosis; HCC = hepatocellular carcinoma; HCV = 




Table 2. Base-Case Number of New Infections and Cost-Effectiveness Results for Baseline, MAT+SSP scale-up, and 
MAT+SSP scale-up with HCV Screening and Treatment Scenarios 
 
Number of New 
Infections* Cost (2016 USD) QALY 
ICER (Inc cost/Inc QALY) 
Intervention 2 vs. baseline** 
Kentucky     
Baseline  4,158 $42,870,668 46,779  




2,306 $64,456,601 49,874 $6,975  
San Francisco     
Baseline  42,221 $1,610,582,798 706,637  




5,748 $2,482,369,200 785,576 $11,044  
DAA = direct-acting antiviral agent; HCV = hepatitis C virus; ICER = incremental cost-effectiveness ratio; MAT = medication-assisted treatment; 
QALY = quality-adjusted life-year; SSP = syringe-service program; PWID = people who inject drugs. 
*Small impact of MAT+SSP on number of new infections is due to the bounce back in the HCV epidemic in both settings after 10 years of 
intervention, such that most infections averted become re-infected throughout the 50-year follow-up. HCV treatment achieves more impact in 




** Intervention 1 is not cost-effective because of extended dominance (i.e., the ICER of Intervention 1 vs baseline is higher than the ICER of 
Intervention 2 versus Intervention 1) 
All estimates are over a 60-year time horizon, the scale-up of MAT+SSP and the screening and HCV treatment lasts 10 years; costs and QALYs 
discounted at 3% annual rate, 2016 prices. Intervention 1 is weakly dominated by Intervention 2 in both settings. Baseline: current levels of SSP 
and MAT with limited, usual care, annual screening and HCV treatment with DAAs for persons who formerly injected drugs; Intervention 1: 
scale-up of SSP and MAT to 50% for 10 years with the same level of screening and HCV treatment for persons who formerly injected drugs as in 
baseline; Intervention 2: scale-up of SSP and MAT, plus annually screening 90% of PWID for HCV, followed by HCV treatment with DAAs for 






Figure 1. Base-case results for Kentucky (a) and San Francisco (b) in the form of cost-
effectiveness acceptability curves (CEACs). 
The CEACs show the probability that one strategy is preferred to the other, for different 
maximum willingness-to-pay (WTP) for an additional quality-adjusted life-year (QALY). As 
decision makers are willing to pay more for an additional QALY, the more-costly and effective 
strategy is preferred. Baseline: current levels of syringe-service program (SSP) and medication-
assisted treatment (MAT) with limited, usual hepatitis C virus (HCV) care including HCV 
screening and treatment with direct-acting antiviral agents (DAAs) for ex-injectors. Intervention 
1: Scale-up of SSP and MAT to 50% coverage with the same level of screening and HCV 
treatment for ex-injectors as in the baseline intervention. Intervention 2: Scale-up of SSP and 
MAT to 50% coverage, plus annually screening of 90% of current injectors for HCV, followed 












Figure 2. Tornado diagram of univariate sensitivity analyses for Kentucky (a) and San 
Francisco (b). 
Shows the change in ICERs (horizontal axis; $/quality-adjusted life-year [QALY]) compared to 
the base-case ICER ($6,975 per QALY for Kentucky and $11,044 per QALY for San Francisco) 
when different model assumptions are changed (see vertical axis). These analyses consider 
Intervention 2 where scale-up of MAT and SSP with hepatitis C virus screening and treatment is 
compared with the baseline scenario. For example, for both settings, Intervention 2 becomes 
more cost-effective (lower ICER) when reducing the cost of DAAs and less cost-effective 
(higher ICER) when decreasing the time horizon of the analysis. 
a. Kentucky 
 
DAA = direct-acting antiviral agent; SSP = syringe-service program; PWID= people who inject 





b. San Francisco 
 
DAA = direct-acting antiviral agent; SSP = syringe-service program; PWID= people who inject 





Appendix 1. Model Structure, Epidemiological Inputs and Assumptions 
There are two models, one for Perry County and one for San Francisco (models are thoroughly 
described in a recently accepted publication by Fraser et al. [15]). Both have the same intervention 
states and risk states (Figure A1-1a), infection states (Figure A1-1b) and disease progression 
stages (Figure A1-c). However, the PWID demographics and injecting drug use dynamics 
differed between the sites; with the Perry County (PC) model stratifying by injecting duration 
(<3 and ≥3 years, Figure A1-d), where PWID injecting <3 years had greater HCV acquisition 
risk (2.2-fold) compared to those injecting ≥3years, and the San Francisco (SF) model stratifying 
by age (15-24, 25-29, 30-49 and 50+ years, Figure A1-e) to capture differences in antibody 
prevalence by age. 
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Figure A1-1a: Schematic showing the transitions of PWID between different intervention and 
risk states for both models. PWID in any state can also be in any infection state, injecting 
duration (Perry County only) or age group (San Francisco only). Note, for clarity demography is 
not shown. White and black arrows represent movement onto and off SSP, respectively, while 
mid grey and dark grey represent movement on and off MAT, respectively. Pale grey dashed 
arrows represent movement from low to high risk, and pale grey arrows with a thick solid line 































Figure A1-1b: Schematic showing the transitions of PWID between different infections states 
for both models. A PWID in any state can also be in any injecting duration (Perry County model 
only), age group (San Francisco model only), intervention or risk state (both models). Note, for 
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Figure A1-1c: Schematic showing HCV disease progression. Note that no demography is shown 
unless related to disease progression states. PWID in the susceptible and previously exposed 
groups do not progress through F0 to compensated cirrhosis, only chronically infected PWID 
(both undiagnosed and diagnosed), those in treatment and those who have failed treatment do. 
From compensated cirrhosis onwards progression amongst susceptible and previously exposed is 
at a slower rate than those chronically infected or who have failed treatment. A PWID in any 
state can also be in any injecting duration (Perry County model only), age group (San Francisco 





Figure A1-1d: Schematic showing the transitions of current PWID between different injecting 
duration states for Perry County. A PWID in any state can also be in any intervention, risk state, 
infection state and disease progression state. Note that those ceasing injecting move to the ex-
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Figure A1-1e: Schematics showing the transitions of current and temporarily ceased PWID 
between different age and injecting states for San Francisco. A PWID in any state can also be in 
any intervention state, risk state, infection state and disease progression state. Note that those 
permanently ceasing injecting from the temporarily ceased group move to the ex-injector 
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Model structure for Perry County, Kentucky 
The modeled PWID population was stratified by injecting duration (<3 yrs, ≥3yrs), high and low 
risk (high risk defined as sharing works in the past 6 months), intervention status (not on MAT or 
SSP, on MAT or SSP only, or on both), HCV infection status (susceptible, previously infected 
(Ab+, RNA-), chronically infected (Ab+, RNA+), in treatment and failed treatment), and disease 
progression status (F0-F3, compensated cirrhosis, decompensated cirrhosis, hepatocellular 
carcinoma (HCC), liver transplant and post-liver transplant) as well as whether a current PWID 
or ex-injector. 
All individuals enter the model as injecting < 3yrs through a time-varying rate of initiating 
injecting, with a proportion entering as low risk and the remainder as high risk. PWID are able to 
transition between high- and low-risk states and gradually transition to the injecting three or 
more years compartment after an average duration of 3 years. PWID that permanently cease 
injecting move into the ex-injector part of the model, where they are stratified by infection stage 
and disease progression only. PWID and ex-injectors leave the model from all compartments due 
to mortality (either drug or non-drug related).  
 
The model simulates HCV transmission at a per-capita transmission rate, which is dependent on 
the prevalence of chronic infection. HCV transmission risk is reduced if PWID are on MAT, SSP 
or both, but increased if they are high risk or have been injecting for < 3yrs. We assume that 
mixing between PWID to form transition contacts can range from random to fully assortative 




All PWID enter the model as F0, susceptible and not on MAT or SSP. Once infected, a 
proportion spontaneously clear infection and move to the previously infected group, while all 
other PWID develop chronic infection. Chronically infected PWID remain infected until they are 
screened and can then be treated, whereupon a proportion achieve a sustained viral response 
(SVR—effective cure) and the remainder move to the treatment failure group, where they are 
still chronically infected. We assume those in the treatment failure group can be re-treated. 
 
Once chronically infected PWID progress through disease progression stages at given rates. 
Those who are treated in the F0-F3 stages and achieve SVR do not progress unless they become 
re-infected. We assume that PWID who have compensated cirrhosis can progress through 
disease stages for all infection states, but those who are not chronically infected do so at a slower 
rate. All individuals with DC or higher disease progression progress at the same rate regardless 
of infection state. 
Model equations for Perry County, Kentucky 
The system is modeled by a set of 918 differential equations. There is an additional infection 
state in the cost-effectiveness model compared to the impact model [15] to account for screening. 
For current injectors, we denote the variables for the infection states in the model by 
𝑆𝑖,𝑗
𝑘,𝑙 = Susceptible PWID 
𝐸𝑖,𝑗
𝑘,𝑙 = Previously exposed PWID (Ab+, RNA-) 
𝐼𝑖,𝑗
𝑘,𝑙 = Chronically infected PWID (Ab+, RNA+) 
𝑅𝑖,𝑗
𝑘,𝑙
 = Screened PWID (chronically infected) 
𝑇𝑖,𝑗
𝑘,𝑙 = PWID in treatment 
𝐹𝑖,𝑗





• 𝑘 – injecting duration (𝑘 = 0 injecting < 3 yrs, 𝑘 = 1 injecting ≥3yrs) 
• 𝑙 – risk status (𝑙 = 0 low risk, 𝑙 = 1 high risk) 
• 𝑖, 𝑗 – MAT and SSP status respectively (𝑖, 𝑗 = 0 not on MAT/SSP, 𝑖, 𝑗 = 1 on MAT/SSP).  
Post-2017 we assume that a proportion of those chronically infected are screened, and a 
proportion of those screened are treated; those that are not treated are assumed lost to follow-up 
and return to the chronically infected compartment. 
 
A susceptible individual can only be in disease progression stage F0. This is because if they 
become infected and spontaneously clear infection they progress to the previously exposed 
compartment. Therefore, there is no disease progression from this group. Any previously 
exposed individual can be in any disease progression stage, however only progresses through 
the disease progression stages if in the compensated cirrhosis or more severe compartments. 
When in the previously exposed compartment, those with compensated cirrhosis progress to 
decompensated cirrhosis or HCC at a slower rate than those with chronic HCV infection. 
 
For individuals in any infection state 𝑌𝑖,𝑗
𝑘,𝑙
 let us add two additional superscripts 𝑚 and 𝑙 (i.e. 
𝑌𝑖,𝑗
𝑘,𝑙,𝑚,𝑛) where 
• 𝑚 represents disease progression: 𝑚 = 0 F0; 𝑚 = 1 F1; 𝑚 = 2 F2; 𝑚 = 3 F3; 𝑚 = 4 
compensated cirrhosis (CC); 𝑚 = 5 decompensated cirrhosis (DC); 𝑚 = 6 
Hepatocellular carcinoma (HCC); 𝑚 = 7 Liver transplant and 𝑚 = 8 post-liver 
transplant. 
𝑛 represents current (𝑛 = 0) or ex-injector (𝑙 = 1). 
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For current injectors in exposed compartments with injecting duration 𝑘, risk state 𝑙 and 



























































0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 −𝑒4𝑎𝑠4𝑎 − 𝑒5𝑏𝑠5𝑏 0 0 0 0
0 0 0 0 𝑒4𝑎𝑠4𝑎 −(𝑠5𝑎 + 𝑠5𝑏 + 𝜇5) 0 0 0
0 0 0 0 𝑒4𝑏𝑠4𝑏 𝑠5𝑎 −(𝑠6 + 𝜇6) 0 0
0 0 0 0 0 𝑠5𝑏 𝑠6 −(𝑠7 + 𝜇7) 0

























































where 𝑠𝑚 represents the rate of progression from disease state 𝑚 to disease state 𝑚 + 1, 𝑠𝑚 
represents the decrease in rate of progression from CC to either DC or HCC if not chronically 
infected and 𝜇𝑚 represents the additional mortality in disease stage 𝑚 due to being in an advance 
disease progression stage. 




























































−𝑠0 0 0 0 0 0 0 0 0
𝑠0 −𝑠1 0 0 0 0 0 0 0
0 𝑠1 −𝑠2 0 0 0 0 0 0
0 0 𝑠2 −𝑠3 0 0 0 0 0
0 0 0 𝑠3 −𝑠4𝑎 − 𝑠5𝑏 0 0 0 0
0 0 0 0 𝑠4𝑎 −(𝑠5𝑎 + 𝑠5𝑏 + 𝜇5) 0 0 0
0 0 0 0 𝑠4𝑏 𝑠5𝑎 −(𝑠6 + 𝜇6) 0 0
0 0 0 0 0 𝑠5𝑏 𝑠6 −(𝑠7 + 𝜇7) 0

























































where 𝑋 represents disease stages 𝐼, 𝑅, 𝑇, 𝐹. 
For ex-injectors, we only track infection stage and disease progression; individuals leaving 
injecting in any risk, intervention state and injecting duration progress into the corresponding 
infection and disease progression stage. We assume treatment, screening and disease progression 
occur in a similar manner to among current injectors.  
 
Model structure for San Francisco 
The modeled PWID population for San Francisco was stratified by intervention status, HCV 
infection and high-risk status in the same way as Kentucky. However, the PWID population in 
San Francisco was stratified by age categories (15-24year olds, 25-29years olds, 30-49years olds 
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and 50+year olds) instead of injecting duration, and PWID were stratified by whether they are 
currently injecting or temporarily ceased injecting. Therefore, individuals move from the 
temporarily ceased compartments to ex-injector compartments only (ie we assume current PWID 
have to have a period of temporary cessation before permanently ceasing injecting). 
 
Individuals enter the modeled population as current injectors into the first three age groups 
through a time-varying rate of initiating injecting, and gradually transition through the age 
groups. We assume a decrease in the recruitment rate of PWID to fit to the aging PWID 
population in San Francisco and assume this decrease occurred between 10 and 30 years ago. 
PWID that are currently injecting can temporarily cease injecting at an age dependent rate. 
Temporarily ceased injectors can either relapse back to injecting or permanently cease injecting, 
transitioning to the ex-PWID groups. All individuals in the model (both injectors and ex-PWID) 
can leave the model through mortality. 
 
HCV transmission occurs in the same way as for the Kentucky model with HCV 
transmission risk being reduced for the different intervention states, but increased if they are high 
risk or young. Infection states and disease progression also occur in the same way as for 
Kentucky. Therefore, the disease progression shown for Kentucky, adapted for the different 






Appendix 2. Additional Information on Cost Inputs 
Screening and diagnosis 
HCV screening and diagnosis followed the guidelines issued by the American 
Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of 
America (IDSA) (http://www.hcvguidelines.org/). The guidelines followed the Centers for 
Disease Control and Prevention (CDC)–recommended testing sequence for identifying current 
hepatitis C virus (HCV) infection, where if the HCV antibody test is reactive, there should be 
further RNA testing and linkage to care if RNA testing is positive. The HCV antibody detection 
was assumed to be performed with a rapid test, which is more frequently used in medication-
assisted therapy (MAT) and syringe services program (SSP) settings and with a population of 
people who inject drugs (PWID). The lab tests performed after a positive RNA test were 
informed by the guidelines and selected with CDC advice. Costs were generated for three 
possible scenarios: (1) screening with rapid test (negative result); (2) screening with rapid test 
(positive result) and diagnosis with a negative RNA test; and (3) screening with rapid test 
(positive result), diagnosis with a positive RNA test, and associated laboratory work. The 
specific components of each scenario are presented in Table A2-1. Costs of pre- and post-test 
counseling come from Cipriano et al. [32] and are based on CDC estimates. Costs were inflated to 
2016 USD using the Bureau of Labor Statistics’ Consumer Price Index for medical care services, 
2000–2016. The costs associated with alcohol, or substance abuse structured screening and brief 
intervention services are from the 2016 Medicare fee schedules. All other costs associated with 









Input Parameter Kentucky San Francisco Reference 
Screening with rapid test (negative result) $35 $28 
 
Cost of pre-test counseling $16 $16 Cipriano, 2012 [32] 
Cost per HCV antibody test $19 $13.00 Medicaid, 2016 [33] 
Screening with rapid test (positive result) 
& diagnosis (negative RNA) 
$105 $79 
 
Cost of pre-test counseling $16 $16 Cipriano, 2012 [32] 
Cost per HCV antibody test $19 $13 Medicaid, 2016 [33] 
Cost of collection of venous blood by 
venipuncture 
$3 $3 
Cost per HCV RNA test $58 $39 
Cost of post-test counseling, negative 
result 
$9 $9 Cipriano, 2012 [32] 
Screening with rapid test (positive result) 
& diagnosis (positive RNA) & labs 
$569 $375 
 
Cost of pre-test counseling $16 $16 Cipriano, 2012 [32] 
Cost per HCV antibody test $19 $13 Medicaid, 2016 [33] 
Cost of collection of venous blood by 
venipuncture 
$3 $3 
Cost per HCV RNA test $58 $39 
Cost of post-test counseling, positive 
result 
$17 $17 Cipriano, 2012 [32] 
Cost of comprehensive metabolic panel $11 $9 Medicaid, 2016 [33] 
Cost of hepatitis B surface antigen $14 $9 
Cost of hepatitis B surface antibody $15 $10 








Input Parameter Kentucky San Francisco Reference 
Cost of hepatitis A antibody $17 $11 
Cost of alcohol and/or substance abuse 
structured screening and brief 
intervention services; 15 to 30 minutes 
$29 
 
Medicare, 2016 [35] 
Cost of HCV genotype test $351 $236 Medicaid, 2016 [33] 
EIA= enzyme immunoassay; ELISA= enzyme-linked immunosorbent assay; HCV= hepatitis C virus. 
MAT and SSP 
Two strategies to manage injecting opioid use were considered: syringe services 
programs (SSPs) and medication-assisted therapy (MAT). Using data from the Beth Israel 
Medical Center/North American Syringe Exchange Network Survey, Nguyen et al. [37] estimated 
the programmatic costs for a limited set of services provided by SSPs, including syringe 
exchange, referrals to off-site services, and “no more than one additional on-site service,” such 
as condom distribution, to calculate the average cost per syringe provided by SSPs. We inflated 
their estimate to 2016 USD, using the BLS Consumer Price Index for medical care services, 
giving us a cost of $0.56 per syringe. 
Data on the prevalence of SSP use among PWID in San Francisco was taken from 
Bluthenthal et al. [85], who recruited a cohort of 696 current PWID in Los Angeles and San 
Francisco to study the characteristics of late initiates to drug injection. Through personal 
communications with Henry Fisher Raymond, PhD, San Francisco Department of Public Health 
(September 25, 2015) and Michael Discepola, MA, Director of Behavioral Health Services, San 
Francisco AIDS Foundation (May 24, 2016), we obtained estimates of the number of PWID and 
the number of syringes exchanged by SSPs in San Francisco in 2015, respectively. Using this 
data, we calculated the number of syringes exchanged per person per year and multiplied this 
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number by the cost per syringe to estimate the total cost per person per year of SSPs. Because 
SSPs have not been in operation long enough in Kentucky to produce sufficient data, we applied 
the cost per person per year from San Francisco to Kentucky (Table A2-2). 
Table A2-2. Calculations of Costs of SSP per Person per Year 
Parameter Value Source 
Unit cost per syringe 
exchanged in NEP 
$0.56 Nguyen et al., 2014 [37] 
Number of syringes per 
person per year 
227.57 Calculated 




Personal communication with Michael Discepola, 2016  
Estimated prevalence 
of SSP use by PWID 
75.10% Bluthenthal, 2015 [33] 
Number of PWID 22,500 Personal communication with Henry Fisher Raymond, 2015  
Cost per person per year $126.67 Calculated 
PWID= people who inject drugs; SSP= syringe services program. 
Notes: Estimates might not add up due to rounding. The number of syringes per person per year = total 
number of syringes exchanged / (estimated prevalence of SSP use by PWID * number of PWID). All 
costs in 2016 prices. 
In the United States, the Substance Abuse and Mental Health Services Administration 
certifies opioid treatment programs (OTPs) to provide MAT with methadone, buprenorphine, 
and extended-release naltrexone (Vivitrol®), the only three opioid medications approved for the 
treatment of opioid addiction. We assumed MAT was provided with methadone. The National 
Survey of Substance Abuse Treatment Services (N-SSATS) found that of the 343,180 clients 
receiving medication-assisted opioid therapy in OTPs, 96 percent (330,308) received methadone, 
4 percent (12,513 clients) received buprenorphine, and less than 1 percent (359) received 
Vivitrol® [86]. The cost per day of methadone treatment per patient was taken from Jackson et al. 
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[36]. The authors conducted an analysis of a sample of 11 state Medicaid programs and single 
state agencies, selected for geographic and population variation. 
HCV treatment 
Treatment costs consist of the costs of antiviral therapy and treatment monitoring. To 
estimate the cost of a course of antiviral therapy, we first determined the distributions of four 
common HCV genotypes (1a, 1b, 2, and 3) among PWID populations in San Francisco and 
Kentucky. Dias et al. [87] provided data on genotype distributions in San Francisco by conducting 
a pooled analysis of three data sources: the Urban Health Study (UHS), the U Find Out study, 
and the Study of the Consequences of the Protease Inhibitor Era. Young et al. [88] described 
characteristics of a cohort of PWID in the Social Networks among Appalachian People (SNAP) 
study. We aggregated the data presented by these authors into four genotypes. 
We next determined the average costs of treatment for each of the four genotypes. We 
followed the guidelines issued by the AASLD and the IDSA (http://www.hcvguidelines.org/) for 
the treatment of HCV, which rate treatment options by strength of evidence. For each genotype, 
we compiled a list of treatment options, for treatment-naïve patients, with evidence derived from 
multiple randomized control trials or meta-analyses. We then obtained the costs associated with 
each of these treatments [89], and took the mean value across all treatments for each genotype. We 
calculated an average cost of treatment for each location (San Francisco and Kentucky) by 
weighting the cost for each genotype with the proportion of PWID in each location with that 
genotype (Table A2-3). 
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Table A2-3. Calculations of Costs of Antiviral Therapy 
 
Value 
Source Parameter San Francisco Kentucky 
Genotype distributions 
   
Genotype 1a 51.20% 69.47% Young, 2012 [88]; 
Dias et al 2011 [87] 
 Genotype 1b 22.94% 
 
Genotype 2 10.22% 16.84% 
Genotype 3 15.64% 13.68% 
Average cost of treatment, genotype 1a $62,565 $62,565 
 
Daily fixed-dose combination of elbasvir (50 
mg)/grazoprevir (100 mg) 12 weeks 
$54,600 $54,600  
Daily fixed-dose combination of glecaprevir 
(300 mg)/pribentasvir (120 mg) for 8 weeks 
$26,400 $26,400 
Daily fixed-dose combination of ledispavir (90 
mg)/sofosbuvir (400 mg) for 12 weeks 
$94,500 $94,500  
Daily fixed-dose combination of sofosbuvir 
(400 mg)/velpatasvir (100 mg) for 12 weeks 
$74,760 $74,760  
Average cost of treatment, genotype 1b $62,565 $62,565  
Daily fixed-dose combination of elbasvir (50 
mg)/grazoprevir (100 mg) for 12 weeks 
$54,600 $54,600  
Daily fixed-dose combination of glecaprevir 
(300 mg)/pribentasvir (120 mg) for 8 weeks 
$26,400 $26,400 
Daily fixed-dose combination of ledispavir (90 
mg)/sofosbuvir (400 mg) for 12 weeks 
$94,500 $94,500 
Daily fixed-dose combination of sofosbuvir 
(400 mg)/velpatasvir (100 mg) for 12 weeks 
$74,760 $74,760 
Average cost of treatment, genotype 2 $50,580 $50,580  
Daily fixed-dose combination of glecaprevir 
(300 mg)/pibrentasvir (120 mg) for 8 weeks 
$26,400 $26,400  
Daily fixed-dose combination of sofosbuvir 
(400 mg)/velpatasvir (100 mg) for 12 weeks 





Source Parameter San Francisco Kentucky 
Average cost of treatment, genotype 3 $50,580 $50,580 
 
Daily glecaprevir (300 mg)/pibrentasvir (120 
mg) for 8 weeks 
$26,400 $26,400  
Daily sofosbuvir (400 mg)/velpatasvir (100 
mg) for 12 weeks 
$74,760 $74,760  
Total cost for course of treatment $59,466 $58,906 
 
Genotype 1a $32,033 $43,466 
 
Genotype 1b $14,353 $0 
 
Genotype 2 $5,169 $8,519 
 
Genotype 3 $7,911 $6,921 
 
Note: Estimates might not add up due to rounding. 
Using the AASLD and IDSA guidelines and CDC input, treatment-monitoring activities 
included weekly clinic visits during up to 12 weeks of treatment; lab tests (e.g., complete blood 
count, creatinine level, calculated glomerular filtration rate, hepatic function panel) every 4 
weeks during up to 12 weeks of treatment; and two HCV viral load testing. We costed each 
monitoring activity using 2016 Medicaid fee schedules for each location (Table A2-4). 
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San Francisco Kentucky Source 
Cost of clinic visits as clinically indicated to 
ensure medication adherence and to monitor 
for adverse events and potential drug-drug 
interactions (established patient 10-minute 
office visit; assume one per week) 
$11 $20 Medicaid, 2016 [33] 
Cost of complete blood count, creatinine 
level, calculated glomerular filtration rate, and 
hepatic function panel after 4 weeks of 
treatment and as clinically indicated (assume 
three times during 12-week period) 
$20 $27 
 
Cost of blood count; complete (CBC), 
automated (Hgb, HCT, RBC, WBC, and 
platelet count) and automated differential 
WBC count 
$6 $9 Medicaid, 2016 [33] 
Cost of BUN/creatinine ratio (calculated), 
calcium, carbon dioxide, chloride, 
creatinine with GFR estimated, glucose, 
potassium, sodium, urea nitrogen (BUN) 
$7 $9 
Cost of albumin, bilirubin (total), bilirubin 
(direct), phosphatase (alkaline), protein 
(total), transferase (alanine amine, SGPT), 
transferase (aspartate amino, SGOT) 
$7 $9 
Cost of quantitative HCV viral load testing 
after 4 weeks of therapy and at 12 weeks 
following completion of therapy 
$39 $58 
Total cost of monitoring $274 $443 
 
BUN= blood urea nitrogen; CBC= complete blood count; GFR= glomerular filtration rate; HCV= 
hepatitis C virus; HCT= hematocrit blood test; Hgb= hemoglobin; RBC= red blood cell; SGOT= serum 
glutamic-oxaloacetic transaminase; SGPT= serum glutamic-pyruvic transaminase; WBC= white blood 
cell. 
Notes: Estimates might not add up due to rounding. We assumed one office visit per week during the 
full course of treatment, lab tests every 4 weeks during the full course of treatment, and HCV 
quantification at 4 and 12 weeks. 
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Appendix 3. Additional Results 
Table A3-1. Additional Base-Case Results for Baseline, MAT+SSP scale-up, and MAT+SSP scale-up with HCV Screening and 
Treatment Scenarios 
 











Number screened 8,750 8,662 21,950 105,068 104,281 384,951 
Total number treated 679 618 694 8,008 7,816 20,798 
Total number achieving SVR 610 556 623 7,186 7,013 18,652 
Number years with CC 10,770 10,041 2,034 274,329 269,420 134,353 
Number years with DC 1,363 1,247 190 41,295 40,614 7,306 
Number years with HCC 198 181 29 5,341 5,246 793 
Number liver transplants 37 33 5 1,094 1,076 200 
Number years post-transplant 332 302 45 14,333 14,174 4,750 
Number infections 4,158 3,907 2,306 42,221 41,175 5,748 
Cost screening* 938,626 851,049 1,385,024 8,331,153 8,171,788 24,405,420 
Cost MAT* 5,906,330 22,938,918 22,988,036 407,944,927 808,054,475 823,057,383 















Cost DAA treatment* 13,178,781 11,785,311 33,622,589 175,487,951 171,599,544 1,161,359,076 
Cost DAA treatment 
monitoring* 
161,096 144,001 408,794 818,081 799,936 5,389,938 
HCV-related complication 
care costs* 
22,294,746 20,486,545 4,204,914 959,277,334 949,304,935 367,030,561 
Costs SVR*^ 391,090 337,844 1,379,880 2,596,267 2,523,380 43,214,777 
Total costs* 42,870,668 57,010,657 64,456,601 1,610,582,798 1,996,599,159 2,482,369,200 
Total QALYs 46,779 47,531 49,874 706,637 714,536 785,576 
Total life-years 159,704 160,869 165,071 2,273,503 2,275,970 2,450,136 
*2016 USD; ^ Costs of SVR are the annual monitoring costs after an individual achieves SVR (Rein et al., 2015).  
CC = compensated cirrhosis; DAA = direct-acting antiviral agent; DC = decompensated cirrhosis; HCC = hepatocellular carcinoma; HCV = 
hepatitis C virus; MAT= medication-assisted treatment; QALY = quality-adjusted life-year; SSP = syringe services program; SVR = sustained 
virologic response. 
All estimates are over a 60-year time horizon, costs and QALYs discounted at 3% annual rate, 2016 prices. Baseline: current levels of SSP and 
MAT with limited, usual care, annual screening and HCV treatment with DAAs for ex-injectors; Intervention 1: scale-up of SSP and MAT to 
50% for 10 years with the same level of screening and HCV treatment for ex-injectors as in baseline; Intervention 2: scale-up of SSP and MAT, 
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plus annually screening 90% of current injectors for HCV, followed by HCV treatment with DAAs for 90% of persons found to be chronically 
infected. The scale-up of MAT+SSP and the screening and HCV treatment lasts 10 years. 
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Figure A3-1. Number of Infections for Baseline, MAT+SSP scale-up (Intervention 1), and 
MAT+SSP scale-up with HCV Screening and Treatment (Intervention 2) for Kentucky (a) 
and San Francisco (b) 
Small impact of MAT+SSP on number of new infections is due to the bounce back in the HCV 
epidemic in both settings after 10 years of intervention, such that most infections averted become 
re-infected throughout the 50-year follow-up. HCV treatment achieves more impact in terms of 
percentage of HCV infections averted in San Francisco due to the much slower bounce back in 












Table A3-2. Sensitivity Analysis for Baseline and MAT+SSP scale-up with HCV Screening and Treatment Scenarios 
 














(b vs. a) 
Base-case 
Number of infections 4,158 2,306 -1,852 42,221 5,748 -36,473 
Life-years 159,704 165,071 5,367 2,273,503 2,450,136 176,632 
QALYs 46,779 49,874 3,095 706,637 785,576 78,939 
Cost, $ 42,870,668 64,456,601 21,585,932 1,610,582,798 2,482,369,200 871,786,402 
ICER, $/ QALY n/a n/a 6,975 n/a n/a 11,044 
Reduce DAA costs by 25% 
Number of infections 4,158 2,306 -1,852 42,221 5,748 -36,473 
Life-years 159,704 165,071 5,367 2,273,503 2,450,136 176,632 
QALYs 46,779 49,874 3,095 706,637 785,576 78,939 
Cost, $ 39,575,973 56,050,953 16,474,980 1,566,710,810 2,192,029,431 625,318,621 


















(b vs. a) 
Reduce DAA costs by 50% 
Number of infections 4,158 2,306 -1,852 42,221 5,748 -36,473 
Life-years 159,704 165,071 5,367 2,273,503 2,450,136 176,632 
QALYs 46,779 49,874 3,095 706,637 785,576 78,939 
Cost, $ 36,281,278 47,645,306 11,364,028 1,522,838,822 1,901,689,662 378,850,839 
ICER, $/ QALY n/a n/a 3,672 n/a n/a 4,799 
Reduce DAA costs by 75% 
Number of infections 4,158 2,306 -1,852 42,221 5,748 -36,473 
Life-years 159,704 165,071 5,367 2,273,503 2,450,136 176,632 
QALYs 46,779 49,874 3,095 706,637 785,576 78,939 
Cost, $ 32,986,583 39,239,659 6,253,076 1,478,966,835 1,611,349,893 132,383,058 
ICER, $/ QALY n/a n/a 2,020 n/a n/a 1,677 
SVR rate reduction 
Number of infections 4,158 2,640 -1,519 42,221 8,192 -34,029 


















(b vs. a) 
QALYs 46,749 49,722 2,973 705,747 783,532 77,785 
Cost, $ 44,867,644 73,075,368 28,207,724 1,637,403,728 2,718,696,042 1,081,292,314 
ICER, $/ QALY n/a n/a 9,489 n/a n/a 13,901 
Total 35 years 
Number of infections 2,424 668 -1,755 24,809 2,773 -22,035 
Life-years 68,584 69,379 794 1,155,345 1,205,494 50,150 
QALYs 29,438 31,170 1,732 499,607 545,239 45,632 
Cost, $ 21,525,634 59,195,897 37,670,264 1,184,766,020 2,329,418,562 1,144,652,542 
ICER, $/ QALY n/a n/a 21,744 n/a n/a 25,084 
Total 110 years 
Number of infections 7,627 5,781 -1,846 76,916 25,819 -51,097 
Life-years 414,734 445,411 30,677 5,030,247 5,662,504 632,257 
QALYs 63,299 68,258 4,959 882,665 997,995 115,330 
Cost, $ 66,350,126 77,870,935 11,520,809 1,933,150,429 2,595,895,269 662,744,840 


















(b vs. a) 
45% screen and 45% treat 
Number of infections 4,158 3,442 -716 42,221 27,660 -14,561 
Life-years 159,704 163,954 4,261 2,273,503 2,411,675 138,172 
QALYs 46,779 49,093 2,314 706,637 767,436 60,798 
Cost, $ 42,870,668 71,197,732 28,327,064 1,610,582,798 2,498,597,698 888,014,900 
ICER, $/ QALY n/a n/a 12,240 n/a n/a 14,606 
Lower utility estimates (based on Wittenberg) 
Number of infections 4,158 2,306 -1,852 42,221 5,748 -36,473 
Life-years 159,704 165,071 5,367 2,273,503 2,450,136 176,632 
QALYs 42,009 45,050 3,041 597,387 671,510 74,123 
Cost, $ 42,870,668 64,456,601 21,585,932 1,610,582,798 2,482,369,200 871,786,402 
ICER, $/ QALY n/a n/a 7,098 n/a n/a 11,761 
Minimum method for calculating QALYs 
Number of infections 4,158 2,306 -1,852 42,221 5,748 -36,473 


















(b vs. a) 
QALYs 49,353 51,934 2,581 779,307 846,059 66,752 
Cost, $ 42,870,668 64,456,601 21,585,932 1,610,582,798 2,482,369,200 871,786,402 
ICER, $/ QALY n/a n/a 8,363 n/a n/a 13,060 
Minimum method for calculating QALYs with lower utility estimates 
Number of infections 4,158 2,306 -1,852 42,221 5,748 -36,473 
Life-years 159,704 165,071 5,367 2,273,503 2,450,136 176,632 
QALYs 43,930 46,599 2,668 648,194 711,819 63,625 
Cost, $ 42,870,668 64,456,604 21,585,932 1,610,582,798 2,482,369,200 871,786,402 
ICER, $/ QALY n/a n/a 8,089 n/a n/a 13,702 
No cost of pre-test counselling 
Number of infections 4,158 2,306 -1,852 42,221 5,748 -36,473 
Life-years 159,704 165,071 5,367 2,273,503 2,450,136 176,632 
QALYs 46,779 49,874 3,095 706,637 785,576 78,939 
Cost, $ 42,825,734 64,212,828 21,387,093 1,610,008,247 2,477,766,823 867,758,576 


















(b vs. a) 
Increase in linkage to treatment after screening (53.8% treated, for diagnosed persons who formerly injected drugs) 
Number of infections 4,158 2,306 -1,852 42,221 5,748 -36,473 
Life-years 161,496 165,308 3,812 2,306,149 2,455,032 148,883 
QALYs 47,382 49,980 2,598 716,093 787,445 71,353 
Cost, $ 56,383,220 68,116,237 11,733,017 1,740,223,335 2,501,965,161 761,741,825 
ICER, $/ QALY n/a n/a 4,516 n/a n/a 10,676 
Increased mortality in first four weeks after starting/cessating MAT 
Number of infections 4,154 2,294 -1,860 42,113 5,709 -36,404 
Life-years 159,367 163,917 4,550 2,264,177 2,434,186 170,009 
QALYs 46,684 49,484 2,800 704,024 780,556 76,532 
Cost, $ 42,700,265 63,923,500 21,223,235 1,602,064,903 2,469,822,936 867,758,033 
ICER, $/ QALY n/a n/a 7,581 n/a n/a 11,338 
Decreased prevalence estimate among those aged over 50 (San Francisco only) 
Number of infections n/a n/a n/a 21,009 1,319 -19,690 


















(b vs. a) 
QALYs n/a n/a n/a 573,519 634,406 60,886 
Cost, $ n/a n/a n/a 1,317,141,430 2,141,333,899 824,192,469 
ICER, $/ QALY n/a n/a n/a n/a n/a 13,537 
HCV = hepatitis C virus; ICER = incremental cost-effectiveness ratio; QALY = quality-adjusted life-year; SSP = syringe-service 
program 
